September 14th 2016
Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor University Medical Center, discusses precision medicine in triple negative breast cancer.
August 17th 2016
Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.